PMID- 19373627
OWN - NLM
STAT- MEDLINE
DCOM- 20090507
LR  - 20151119
IS  - 1532-4303 (Electronic)
IS  - 0277-0903 (Linking)
VI  - 46
IP  - 3
DP  - 2009 Apr
TI  - Sequential evaluation of serum monocyte chemotactic protein 1 among asymptomatic 
      state and acute exacerbation and remission of asthma in children.
PG  - 225-8
LID - 10.1080/02770900802553805 [doi]
AB  - BACKGROUND: Monocyte chemotactic protein 1 (MCP-1) plays an important role in 
      various immune and allergic disorders since it is a potent chemo-attractant for 
      inflammatory cells, such as eosinophils, memory T cells, and monocytes. 
      OBJECTIVE: To investigate serum MCP-1 during asymptomatic state and acute attacks 
      of bronchial asthma. METHODS: In this longitudinal cohort design study, 
      sequential serum levels of MCP-1 were measured by a sandwich enzyme-linked 
      immunosorbent assay (ELISA). Twenty-four asthma patients' MCP-1 levels were 
      examined at 5 time points: during the asymptomatic phase, in an acute wheezing 
      episode, and at 1 week, 1 month, and 2 months after acute asthma attack. Fifteen 
      children without asthma were enrolled as control. RESULTS: During the 
      asymptomatic phase of asthma, serum MCP-1 levels were significantly higher than 
      that of normal controls (329.57 +/- 99.20 pg/ml vs. 213.63 +/- 77.29 pg/ml, p = 
      0.001). In comparison with the asymptomatic phase, the serum MCP-1 levels during 
      the acute asthma attack were significantly higher (682.88 +/- 88.45 pg/ml vs. 
      329.57 +/- 99.20 pg/ml, p < 0.001). After treatment of acute asthma exacerbation, 
      all of the serum MCP-1 levels declined within 1 week, but were still higher than 
      control 2 months later. CONCLUSION: In asthma patients, the consistently elevated 
      serum levels of MCP-1 suggest its role in the pathogenesis of bronchial asthma - 
      not only in the chronic inflammatory processes, but also in acute asthma attack 
      exacerbation. These findings suggest a possible role for MCP-1 in the 
      pathogenesis of asthma and a potential role for its use in anti-asthma treatment 
      in the future.
FAU - Chan, Chin-Kan
AU  - Chan CK
AD  - Graduate Institute of Clinical Medical Science, Chang Gung University, Taoyuan, 
      Taiwan.
FAU - Kuo, Ming-Ling
AU  - Kuo ML
FAU - Yeh, Kuo-Wei
AU  - Yeh KW
FAU - Ou, Liang-Shiou
AU  - Ou LS
FAU - Chen, Li-Chen
AU  - Chen LC
FAU - Yao, Tsung-Chieh
AU  - Yao TC
FAU - Huang, Jing-Long
AU  - Huang JL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Asthma
JT  - The Journal of asthma : official journal of the Association for the Care of 
      Asthma
JID - 8106454
RN  - 0 (Androstadienes)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Chemokine CCL2)
RN  - CUT2W21N7U (Fluticasone)
RN  - N8ONU3L3PG (Terbutaline)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Androstadienes/therapeutic use
MH  - Asthma/*blood/drug therapy
MH  - Bronchodilator Agents/therapeutic use
MH  - Chemokine CCL2/biosynthesis/*blood
MH  - Child
MH  - China
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Fluticasone
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Respiratory Function Tests
MH  - Terbutaline/therapeutic use
EDAT- 2009/04/18 09:00
MHDA- 2009/05/08 09:00
CRDT- 2009/04/18 09:00
PHST- 2009/04/18 09:00 [entrez]
PHST- 2009/04/18 09:00 [pubmed]
PHST- 2009/05/08 09:00 [medline]
AID - 910512135 [pii]
AID - 10.1080/02770900802553805 [doi]
PST - ppublish
SO  - J Asthma. 2009 Apr;46(3):225-8. doi: 10.1080/02770900802553805.